Plerixafor (Mozobil®) is recommended as an option for restricted use within NHS Wales in combination with granulocyte-colony stimulating factor (G-CSF) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with lymphoma and multiple myeloma whose cells mobilise poorly. Plerixafor (Mozobil®) should be restricted for use specifically in patients with non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM) who have already failed one complete mobilisation attempt. AWMSG is of the opinion that plerixafor (Mozobil®) is not suitable for shared care within NHS Wales.